The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Open accessAbstract
Therapies that target the programmed death-1 (PD-1) receptor have shown unprecedented rates of durable clinical responses in patients with various cancer types. One mechanism by which cancer tissues limit the host immune response is via upregulation of PD-1 ligand (PD-L1) and its ligation to PD-1 on antigen-specific CD8+ T cells (termed adaptive immune resistance). Here we show that pre-existing CD8+ T cells distinctly located at the invasive tumour margin are associated with expression of the PD-1/PD-L1 immune inhibitory axis and may predict response to therapy. We analysed samples from 46 patients with metastatic melanoma obtained before and during anti-PD-1 therapy (pembrolizumab) using quantitative immunohistochemistry, quantitative multiplex immunofluorescence, and next-generation sequencing for T-cell antigen receptors (TCRs). In serially sampled tumours, patients responding to treatment showed proliferation of intratumoral CD8+ T cells that directly correlated with radiographic reduction in tumour size. Pre-treatment samples obtained from responding patients showed higher numbers of CD8-, PD-1- and PD-L1-expressing cells at the invasive tumour margin and inside tumours, with close proximity between PD-1 and PD-L1, and a more clonal TCR repertoire. Using multivariate analysis, we established a predictive model based on CD8 expression at the invasive margin and validated the model in an independent cohort of 15 patients. Our findings indicate that tumour regression after therapeutic PD-1 blockade requires pre-existing CD8+ T cells that are negatively regulated by PD-1/PD-L1-mediated adaptive immune resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“TILs are therefore under active investigation as a biomarker to guide selection of patients for treatment with ICT, although significant variability exists in definitions and thresholds (149, 150).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [149]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, both PDL-1 expression and TMB fail to encapsulate various tumor microenvironmental features influencing ICI responses15–17.”
From Predicting the tumor microenvironment composition and immunotherapy response in non-small cell lung cancer from digital histopathology images (2024) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Pre-treatment CD8+ T cell presence is linked to responses to ICB and anti-PD-1 plus lenvatinib in HCC patients.”
From Contrasting cytotoxic and regulatory T cell responses underlying distinct clinical outcomes to anti-PD-1 plus lenvatinib therapy in cancer (2025) · cites this paper as [4]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“We compared the tumor-associated immune infiltrates via multi-parameter immunohistochemistry (IHC) and observed a higher density of CD8+ T cells in baseline samples of R versus NR (p=0.04), consistent with prior reports (Fig. 4A and fig. S18) (18, 37).”
From Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients (2018) · cites this paper as [37]
In the citing paper
“Additionally, cancer cells can increase immune checkpoint molecules such as PD-L1, resulting in peripheral T cell exhaustion and the inhibition of malignant cell apoptosis [85].”
From Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy (2024) · cites this paper as [85]
In the citing paper
“Indeed, as mentioned in the previous section, both PD-1 and CTLA-4 blockades are more effective in tumors that are infiltrated by T cells or that have high mutation rates and are therefore more immunogenic prior to treatment (86–88).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [88]
In the citing paper
“An increase in CD8+ T cell proliferation within the tumor lesion and an increased frequency of Th9 cells in the patients’ circulation were also associated with treatment response (88, 91, 92).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [88]
In the citing paper
“Other pre-treatment immunological factors associated with improved treatment responses include high eosinophil and lymphocyte blood counts, an abundance of CD8+ T cells infiltrating the tumor or present at the tumor margin, and increased serum TGF-β levels in melanoma patients treated with anti-PD-1 (88, 91, 92, 109).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [88]
In the citing paper
“The presence of CD8+ T cells at tumor margins and within the tumor prior to treatment with checkpoint inhibitors was associated with a stronger response to treatment (Tumeh et al., 2014).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Tumeh et al., 2014
In the citing paper
“abundance of T cells at the invasive tumor margin prior to treatment was associated with a better response, whereas upon treatment, T cell densities were increased both at the margin and within the tumor parenchyma in responding patients”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Tumeh et al., 2014
In the citing paper
“In metastatic melanoma patients, a higher density of intratumoral CD8+ T cells at baseline was shown to predict favorable response to anti-PD-1 treatment”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Tumeh et al., 2014
In the citing paper
“some studies have found that high TCR diversity in peripheral blood and tumors prior to ICI therapy is predictive of effective treatment, others have pointed to ICI therapy-associated increases in TCR clonality, that is, enrichment of T cells with the same TCRs, as a sign of effective therapy (150, 157-161).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [150]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., DAUD, A. I., Hodi, F. S., Hwu, W., Kefford, R. F., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,427
Self-citationIntratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397
Wolchok, J. D., Hoos, A., O'Day, S. J., Weber, J. S., Hamid, O., Lebbé, C., Maio, M., Binder, M., Bohnsack, O., Nichol, G. M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1624 · Cited by 3,214
Cited by
Sorted by citations
Items 901–1,000 of 1,060
Gupta, R. G., Li, F., Roszik, J., & Lizee, G. A. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1575 · Cited by 144
“Targeted TCR sequencing in patients with advanced melanoma has demonstrated that higher levels of pre-treatment intratumoral T-cell clonality arising from neoantigen-specific clonal expansion is associated with improved response to ICI therapy and propagated during the course of treatment (98).”
BackgroundBruand, M., Barras, D., Mina, M., Ghisoni, E., Morotti, M., Lanitis, E., Fahr, N., Desbuisson, M., Grimm, A. J., Zhang, H., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109412 · Cited by 146
“The mechanisms leading to TIL infiltration in tumors are under intense investigation since those with pre-existing TILs are more likely to respond to immune checkpoint blockade (ICB) therapy (Thommen et al., 2018; Tumeh et al., 2014).”
BackgroundPai, C.-C. S., Huang, J. T., Lu, X., Simons, D. M., Park, C., Chang, A., Tamaki, W., Liu, E., Roybal, K. T., Seagal, J., et al. (2019) · Immunity · doi:10.1016/j.immuni.2019.01.006 · Cited by 141
“These include adaptive resistance mediated by interferon-dependent expression of inhibitory ligands on cancer cells (Benci et al., 2016; Tumeh et al., 2014), exclusion of CD8 T cell infiltration by transforming growth factor-b (TGF-b) signaling”
Perspectives in the treatment of pancreatic adenocarcinoma
Arregui, A. C. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i31.9297 · Cited by 146
A new paradigm for tumor immune escape: β-catenin-driven immune exclusion
Spranger, S., & Gajewski, T. F. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0089-6 · Cited by 141
Targeting the Heterogeneity of Cancer with Individualized Neoepitope Vaccines
Türeci, Ö., Vormehr, M., Diken, M., Kreiter, S., Huber, C., & Şahin, U. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1509 · Cited by 148
Immunoscore and Immunoprofiling in cancer: an update from the melanoma and immunotherapy bridge 2015
Galon, J., Fox, B. A., Bifulco, C. B., Masucci, G. V., Rau, T. T., Botti, G., Marincola, F. M., Ciliberto, G., Pagès, F., Ascierto, P. A., et al. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-016-1029-z · Cited by 147
de Masson, A., O’Malley, J. T., Elco, C. P., Garcia, S. S., Divito, S. J., Lowry, E. L., Tawa, M. C., Fisher, D. C., Devlin, P. M., Teague, J. E., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aar5894 · Cited by 145
Self-citationHoecke, L. V., Lint, S. V., Roose, K., Parys, A. V., Vandenabeele, P., Grooten, J., Tavernier, J. H., Koker, S. D., & Saelens, X. (2018) · Nature Communications · doi:10.1038/s41467-018-05979-8 · Cited by 146
Tobin, J. W. D., Keane, C., Gunawardana, J., Mollee, P. N., Birch, S. E., Hoang, T., Lee, J. N., Li, L., Huang, L., Murigneux, V., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.02365 · Cited by 141
“Those with immune infiltration tumors have better outcomes with conventional therapy and checkpoint blockade.(12,14) Of interest, similar to our findings in FL, low PD-L2 expression is superior to PD-L1 as a measure of immune infiltration that has been demonstrated to be adversely associated with outcomes in metastati…”
BackgroundResultWang, G., Chow, R. D.-W., Zhu, L., Bai, Z., Ye, L., Zhang, F., Renauer, P. A., Dong, M. B., Dai, X., Zhang, X., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1448 · Cited by 143
“Several factors, including PD-L1 expression, tumor mutation burden (16), neoantigen burden (17), and immune infiltration status (18, 19), as well as certain oncogenic pathways (20), have been demonstrated to be correlated with immunotherapy response.”
BackgroundWang, T.-B., Guo, K., Zhang, D., Wang, H., Yin, J., Cui, H., & Wu, W. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110368 · Cited by 141
The opposing roles of CD 4+ T cells in anti‐tumour immunity
Ahrends, T., & Borst, J. G. (2018) · Immunology · doi:10.1111/imm.12941 · Cited by 144
The emergence of drug resistance to targeted cancer therapies: Clinical evidence
Sarmento‐Ribeiro, A. B., Scorilas, A., Gonçalves, A. C., Efferth, T., & Trougakos, I. P. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100646 · Cited by 145
Immune-mediated mechanisms influencing the efficacy of anticancer therapies
Coffelt, S. B., & de Visser, K. E. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.02.006 · Cited by 147
Biomarkers for Immunotherapy: Current Developments and Challenges
Spencer, K. R., Wang, J., Silk, A. W., Ganesan, S., Kaufman, H. L., & Mehnert, J. M. (2016) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_160766 · Cited by 148
Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies
Garber, S. T., Hashimoto, Y., Weathers, S.-P. S., Xiu, J., Gatalica, Z., Verhaak, R. G. W., Zhou, S., Fuller, G. N., Khasraw, M., de Groot, J., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now132 · Cited by 140
Ge, R., Liu, C., Zhang, X., Wang, W., Li, B., Liu, J., Liu, Y., Sun, H., Zhang, D., Hou, Y., et al. (2018) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.8b05876 · Cited by 139
Hu, C., He, X., Chen, Y., Yang, X., Qin, L., Lei, T., Zhou, Y., Gong, T., Huang, Y., & Gao, H. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202007149 · Cited by 137
A Burned-Out CD8+ T-cell Subset Expands in the Tumor Microenvironment and Curbs Cancer Immunotherapy
Sanmamed, M. F., Nie, X., Desai, S., Villarroel‐Espíndola, F., Badri, T., Zhao, D., Kim, A. W., Ji, L., Zhang, T., Quinlan, E., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0962 · Cited by 140
Supercharging adoptive T cell therapy to overcome solid tumor–induced immunosuppression
Mardiana, S., Solomon, B., Darcy, P. K., & Beavis, P. A. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw2293 · Cited by 140
Lee, Y. H., Tai, D. W.-M., Yip, C., Choo, S. P., & Chew, V. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.568759 · Cited by 139
Dual Roles of IL-27 in Cancer Biology and Immunotherapy
Fabbi, M., Carbotti, G., & Ferrini, S. (2017) · Mediators of Inflammation · doi:10.1155/2017/3958069 · Cited by 140
Yang, W., Wong, M. C. M., Thomson, P. J., Li, K. Y., & Su, Y. (2018) · Oral Oncology · doi:10.1016/j.oraloncology.2018.09.016 · Cited by 136
Thompson, J. C., Hwang, W., Davis, C. W., Deshpande, C. G., Jeffries, S., Rajpurohit, Y. R., Krishna, V., Smirnov, D. S., Verona, R. I., Lorenzi, M. V., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.10.012 · Cited by 140
Design and application of oncolytic viruses for cancer immunotherapy
Ylösmäki, E. O., & Cerullo, V. (2019) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2019.11.016 · Cited by 138
Dendritic Cells, the T-cell-inflamed Tumor Microenvironment, and Immunotherapy Treatment Response
Garris, C., & Luke, J. J. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1321 · Cited by 146
Oba, T., Long, M. D., Keler, T., Marsh, H. C., Minderman, H., Abrams, S. I., Liu, S., & Ito, F. (2020) · Nature Communications · doi:10.1038/s41467-020-19192-z · Cited by 140
Hong, J. Y., Cho, H. J., Sa, J. K., Liu, X., Ha, S. Y., Lee, T., Kim, H., Kang, W., Sinn, D. H., Gwak, G., et al. (2022) · Genome Medicine · doi:10.1186/s13073-021-00995-8 · Cited by 136
Whole-body CD8+ T cell visualization before and during cancer immunotherapy: a phase 1/2 trial
de Ruijter, L. K., van de Donk, P. P., Hooiveld-Noeken, J. S., Giesen, D., Elias, S. G., Hooge, M. N. L., Oosting, S. F., Jalving, M., Timens, W., Brouwers, A. H., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02084-8 · Cited by 136
Layer, J. P., Kronmüller, M., Quast, T., Konijnenberg, D., Effern, M., Hinze, D., Althoff, K., Schramm, A. R., Westermann, F., Peifer, M., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1320626 · Cited by 138
Precision immunoprofiling by image analysis and artificial intelligence
Koelzer, V. H., Sirinukunwattana, K., Rittscher, J., & Mertz, K. D. (2018) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-018-2485-z · Cited by 148
T‐cell receptor profiling in cancer
Kirsch, I. R., Vignali, M., & Robins, H. S. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.09.003 · Cited by 135
Self-citationPeng, L., Chen, Z., Chen, Y., Wang, X., & Tang, N. (2019) · Cancer Medicine · doi:10.1002/cam4.2583 · Cited by 137
Progress and perspective of microneedle system for anti-cancer drug delivery
Li, D., Hu, D., Xu, H., Patra, H. K., Liu, X., Zhou, Z., Tang, J., Slater, N. K. H., & Shen, Y. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120410 · Cited by 135
“[177] Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJM, Robert L, et al.”
BackgroundPredicting recognition between T cell receptors and epitopes with TCRGP
Jokinen, E., Huuhtanen, J., Mustjoki, S. M., Heinonen, M., & Lähdesmäki, H. J. (2021) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1008814 · Cited by 142
Huang, X.-Z., Gao, P., Song, Y.-X., Xu, Y., Sun, J.-X., Chen, X.-W., Zhao, J.-H., & Wang, Z.-N. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1665973 · Cited by 132
“ICI immunotherapy has revolutionized cancer therapy for several solid tumors, and the anti-tumor response to ICIs is enhanced by inhibiting the PD-1 or CTLA-4 pathways and subsequently reactivating the host’s immune function.(30-32) Although the Table 1.”
BackgroundInoue, H., Park, J., Kiyotani, K., Zewde, M. G., Miyashita, A., Jinnin, M., Kiniwa, Y., Okuyama, R., Tanaka, R., Fujisawa, Y., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1204507 · Cited by 137
Immune checkpoint blockade therapy
Wieder, T., Eigentler, T., Brenner, E., & Röcken, M. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.02.042 · Cited by 134
A pilot study of durvalumab and tremelimumab and immunogenomic dynamics in metastatic breast cancer
Santa-Maria, C. A., Kato, T., Park, J.-H., Kiyotani, K., RADEMAKER, A. W., Shah, A. N., Gross, L., Blanco, L. Z., Jain, S., Flaum, L., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24867 · Cited by 137
Infiltration of CD8 + T cells into tumor cell clusters in triple-negative breast cancer
Li, X., Gruosso, T., Zuo, D., Ömeroğlu, A., Meterissian, S. H., Guiot, M., Salazar, A., Park, M., & Levine, H. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1817652116 · Cited by 132
RIG-I activation is critical for responsiveness to checkpoint blockade
Heidegger, S. M., Wintges, A., Stritzke, F., Bek, S., Steiger, K., Koenig, P.-A., Göttert, S., Engleitner, T., Öllinger, R., Nedelko, T., et al. (2019) · Science Immunology · doi:10.1126/sciimmunol.aau8943 · Cited by 136
Discovery of low-molecular weight anti-PD-L1 peptides for cancer immunotherapy
Liu, H., Zhao, Z., Zhang, L., Li, Y., Jain, A., Barve, A. J., Jin, W., Liu, Y., Fetse, J., & Cheng, K. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0705-y · Cited by 134
Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target
Qian, W., Zhao, M., Wang, R., & Li, H. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01161-8 · Cited by 139
Predicting prognosis and therapeutic response from interactions between lymphocytes and tumor cells
Quigley, D. A., & Kristensen, V. N. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.10.003 · Cited by 132
Treatment of lung adenocarcinoma by molecular-targeted therapy and immunotherapy
Saito, M., Suzuki, H. Y., Kono, K., Takenoshita, S., & Kohno, T. (2017) · Surgery Today · doi:10.1007/s00595-017-1497-7 · Cited by 135
Zhang, W., Wang, Y., Guo, Y., Dai, H., Yang, Q., Zhang, Y.-J., Zhang, Y., Chen, M., Wang, C., Feng, K., et al. (2016) · Signal Transduction and Targeted Therapy · doi:10.1038/sigtrans.2016.2 · Cited by 136
Immune System Evasion as Hallmark of Melanoma Progression: The Role of Dendritic Cells
Tucci, M., Passarelli, A. M., Mannavola, F., Felici, C., Stucci, L. S., Cives, M., & Silvestris, F. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01148 · Cited by 139
Yuba, E. (2020) · Journal of Materials Chemistry B · doi:10.1039/c9tb02470k · Cited by 134
Jin, Z. Y., Guo, C. J., Xiong, F., Yu, J., Ge, J., Wang, H., Liao, Q., Zhou, Y., Gong, Q., Xiang, B., et al. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.02.010 · Cited by 138
Li, J., Yuan, S., Norgard, R. J., Yan, F., Sun, Y. H., Kim, I., Merrell, A. J., Sela, Y., Jiang, Y., Bhanu, N. V., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0519 · Cited by 136
Immunotherapeutic interventions of Triple Negative Breast Cancer
Li, Z., Qiu, Y., Lu, W., Jiang, Y., & Wang, J. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1514-7 · Cited by 137
Brenner, E., Schörg, B. F., Ahmetlić, F., Wieder, T., Hilke, F. J., Simon, N., Schroeder, C., Demidov, G. M., Riedel, T., Fehrenbacher, B., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14987-6 · Cited by 136
Highly immunogenic cancer cells require activation of the WNT pathway for immunological escape
Takeuchi, Y., Tanegashima, T., Sato, E., Irie, T., Sai, A., Itahashi, K., Kumagai, S., Tada, Y., Togashi, Y., Koyama, S., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abc6424 · Cited by 134
Núñez, N. G., Berner, F., Friebel, E., Unger, S., Wyss, N., Gómez, J. M. M., Purde, M.-T., Niederer, R., Porsch, M., Lichtensteiger, C., et al. (2023) · Med · doi:10.1016/j.medj.2022.12.007 · Cited by 142
The landscape of T cell antigens for cancer immunotherapy
Peri, A., Salomon, N., Wolf, Y., Kreiter, S., Diken, M., & Samuels, Y. (2023) · Nature Cancer · doi:10.1038/s43018-023-00588-x · Cited by 140
Beatty, G. L., & O’Hara, M. H. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.06.010 · Cited by 131
Joneja, U., Vranić, S., Swensen, J. J., Feldman, R. A., Chen, W., Kimbrough, J., Xiao, N., Reddy, S. K., Palazzo, J., & Gatalica, Z. (2016) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2016-203874 · Cited by 130
Molecular Targeted Drugs and Treatment of Colorectal Cancer: Recent Progress and Future Perspectives
Geng, F., Wang, Z., Yin, H. H., Yu, J., & Cao, B. (2017) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2017.2210 · Cited by 132
Mechanisms of Resistance to Immune Checkpoint Blockade
Liu, D., Jenkins, R. W., & Sullivan, R. J. (2018) · American Journal of Clinical Dermatology · doi:10.1007/s40257-018-0389-y · Cited by 135
Toll-Like Receptor 9 Agonists in Cancer
Karapetyan, L., Luke, J. J., & Davar, D. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s247050 · Cited by 138
Klement, J. D., Redd, P. S., Lu, C., Merting, A. D., Poschel, D. B., Yang, D., Savage, N. M., Zhou, G., Munn, D. H., Fallon, P. G., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.02.005 · Cited by 137
Interferons and the immunogenic effects of cancer therapy
Minn, A. J. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.09.007 · Cited by 130
Obeid, J. M., Erdag, G., Smolkin, M. E., Deacon, D. H., Patterson, J. W., Chen, L., Bullock, T. N. J., & Slingluff, C. L. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1235107 · Cited by 130
Rashidian, M., LaFleur, M. W., Verschoor, V. L., Dongre, A., Zhang, Y., Nguyen, T. H., Kolifrath, S. C., Aref, A. R., Lau, C. J., Paweletz, C. P., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1905005116 · Cited by 131
“Biopsies of skin lesions from patients with metastatic melanoma and analyzed for CD8 T-cell infiltration status and clonality before and after PD-1 blockade treatment showed significant expansion of T cells in the TME in responders (34).”
Backgroundde Rodas, M. L., Nagineni, V., Ravi, A., Datar, I. J., Mino-Kenudson, M. A., Corredor, G., Barrera, C., Behlman, L., Rimm, D. L., Herbst, R. S., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004440 · Cited by 132
Yong, T., Wei, Z., Gan, L., & Yang, X. (2022) · Advanced Materials · doi:10.1002/adma.202201054 · Cited by 129
Kumar, S., Chatterjee, M., Ghosh, P., Ganguly, K. K., Basu, M., & Ghosh, M. K. (2022) · Genes & Diseases · doi:10.1016/j.gendis.2022.07.024 · Cited by 135
“Presence of increased TILs at tumor site are associated with greater efficacy to immune checkpoint blockade.(53) Breast tumor microenvironment are highly heterogeneous and along with cancer cells it consists of various immune cells such as CD8þ T cells, CD4þ T-helper cells, T-regs, gammadelta T cells, macrophages, mas…”
BackgroundTrial Watch: Immunomodulatory monoclonal antibodies for oncological indications
Buqué, A., Bloy, N., Aranda, F., Castoldi, F., Eggermont, A. M. M., Cremer, I., Fridman, W. H., Fucikova, J. P., Galon, J., Marabelle, A., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1008814 · Cited by 132
Feng, Z., Puri, S., Moudgil, T. L., Wood, W. J., Hoyt, C. C., Wang, C., Urba, W. J., Curti, B. D., Bifulco, C. B., & Fox, B. A. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0091-z · Cited by 130
The Impact of PD-L1 Expression in Patients with Metastatic GEP-NETs
Kim, S. T., Ha, S. Y., Lee, S., Ahn, S., Lee, J., Park, S. H., Park, J. O., Lim, H. Y., Kang, W. K., Kim, K., et al. (2016) · Journal of Cancer · doi:10.7150/jca.13711 · Cited by 131
Uruga, H., Bozkurtlar, E. B., Huynh, T. G., Muzikansky, A., Goto, Y., Gomez‐Caraballo, M., Hata, A. N., Gainor, J. F., Mark, E. J., Engelman, J. A., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.10.015 · Cited by 133
Functional Expression of Programmed Death-Ligand 1 (B7-H1) by Immune Cells and Tumor Cells
Johnson, R. M. G., & Dong, H. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00961 · Cited by 131
Targeting DDR2 enhances tumor response to anti–PD-1 immunotherapy
Tu, M. M., Lee, F. Y., Jones, R. T., Kimball, A. K., Saravia, E., Graziano, R. F., Coleman, B. M., Menard, K., Yan, J., Michaud, E., et al. (2019) · Science Advances · doi:10.1126/sciadv.aav2437 · Cited by 133
“The presence of CD8 T cells in the tumor microenvironment and the expansion of preexisting, tumor antigen–specific T cell clones are also critical and predictive of a favorable response with anti–PD-1 therapy (23).”
BackgroundZou, Y., Zou, X., Zheng, S., Tang, H., Zhang, L., Liu, P., & Xie, X. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920940928 · Cited by 131
A Public Database of Memory and Naive B-Cell Receptor Sequences
DeWitt, W. S., Lindau, P., Snyder, T. M., Sherwood, A., Vignali, M., Carlson, C. S., Greenberg, P. D., Duerkopp, N., Emerson, R., & Robins, H. S. (2016) · PLoS ONE · doi:10.1371/journal.pone.0160853 · Cited by 123
Self-citationDevelopment of individualized anti-metastasis strategies by engineering nanomedicines
He, Q., Guo, S., Qian, Z., & Chen, X. S. (2015) · Chemical Society Reviews · doi:10.1039/c4cs00511b · Cited by 130
Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1
Bertucci, F., & Gonçalvès, A. (2017) · Current Oncology Reports · doi:10.1007/s11912-017-0627-0 · Cited by 129
The beginning of the end for conventional RECIST — novel therapies require novel imaging approaches
Gerwing, M., Herrmann, K., Helfen, A., Schliemann, C., Berdel, W. E., Eisenblätter, M., & Wildgruber, M. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0169-5 · Cited by 130
VISTA: Coming of age as a multi-lineage immune checkpoint
ElTanbouly, M. A., Schaafsma, E., Noelle, R. J., & Lines, J. L. (2020) · Clinical & Experimental Immunology · doi:10.1111/cei.13415 · Cited by 131
PD-1 Inhibitors: Do they have a Future in the Treatment of Glioblastoma?
Khasraw, M., Reardon, D. A., Weller, M., & Sampson, J. H. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1135 · Cited by 129
“These immune cells can either be reinvigorated or expanded by PD-L1/PD-1 inhibition, leading to recognition and targeting of cancer (30, 31).”
BackgroundPD-1/PD-L1 in Cancer: Pathophysiological, Diagnostic and Therapeutic Aspects
Munari, E., Mariotti, F. R., Quatrini, L., Bertoglio, P., Tumino, N., Vacca, P., Eccher, A., Ciompi, F., Brunelli, M., Martignoni, G., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105123 · Cited by 135
Nosrati, A., Tsai, K. K., Goldinger, S. M., Tumeh, P. C., Grimes, B. A., Loo, K. L., Algazi, A. P., Nguyen‐Kim, T. D. L., Levesque, M. P., Dummer, R., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.70 · Cited by 126
Self-citationHong, X., Sullivan, R. J., Kalinich, M., Kwan, T. T., Giobbie‐Hurder, A., Pan, S., LiCausi, J. A., Milner, J. D., Nieman, L. T., Wittner, B. S., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1719264115 · Cited by 129
Spatially mapping the immune landscape of melanoma using imaging mass cytometry
Moldoveanu, D., Ramsay, L., Lajoie, M., Anderson-Trocmé, L., Lingrand, M., Berry, D., Perus, L. J. M., Wei, Y., Moraes, C., Alkallas, R., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abi5072 · Cited by 125
“For instance, the proximity of PD1 to its PD-L1 ligand correlates with improved response to anti-PD1 immunotherapy in multiplexed immunofluorescence analyses of pretreatment melanoma samples (6).”
BackgroundInfluentialXie, X., Yang, Y., Wang, Q., Liu, H.-F., Fang, X., Li, C., Jiang, Y., Wang, S., Zhao, H., Miao, J., et al. (2023) · Cell Research · doi:10.1038/s41422-022-00766-z · Cited by 130
Combination of Immunotherapy With Targeted Therapy: Theory and Practice in Metastatic Melanoma
Yu, C., Liu, X., Yang, J., Zhang, M., Jin, H., Ma, X., & Shi, H. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00990 · Cited by 126
“The expression of PD-L1 in tumors may be an indicator for the prognosis (72, 73).”
BackgroundBertucci, F., Finetti, P., Colpaert, C., Mamessier, É., Parizel, M., Dirix, L. Y., Viens, P., Birnbaum, D., & Laere, S. V. (2015) · Oncotarget · doi:10.18632/oncotarget.3642 · Cited by 125
Quantitative CD3 PET Imaging Predicts Tumor Growth Response to Anti-CTLA-4 Therapy
Larimer, B. M., Wehrenberg-Klee, E. P., Caraballo, A., & Mahmood, U. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.173930 · Cited by 127
Kim, K. J., Kim, J. H., Lee, S. J., Lee, E., Shin, E., & Seong, J. (2017) · Oncotarget · doi:10.18632/oncotarget.17168 · Cited by 125
Challenges for immunotherapy for the treatment of platinum resistant ovarian cancer
Saux, O. L., Ray-Coquard, I. L., & Labidi‐Galy, S. I. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.08.017 · Cited by 127
Pancreatic cancer in 2021: What you need to know to win
Tonini, V., & Zanni, M. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i35.5851 · Cited by 133
Horton, B. L., Morgan, D. M., Momin, N., Zagorulya, M., Torres-Mejia, E., Bhandarkar, V., Wittrup, K. D., Love, J. C., & Spranger, S. (2021) · Science Immunology · doi:10.1126/sciimmunol.abi8800 · Cited by 124
“We focused our subsequent analysis on the two non- naïve CD8+ T cell clusters (CD8+ c1 and CD8+ c2) (6, 17, 18).”
MethodZhao, C., Song, W., Wang, J., Tang, X., & Jiang, Z. (2024) · Chemical Communications · doi:10.1039/d4cc06510g · Cited by 128
Tumor microenvironment (TME)-driven immune suppression in B cell malignancy
Nicholas, N. S., Apollonio, B., & Ramsay, A. G. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2015.11.003 · Cited by 131
Mahoney, K. M., Sun, H. H., Liao, X., Hua, P., Callea, M., Greenfield, E. A., Hodi, F. S., Sharpe, A. H., Signoretti, S., Rodig, S. J., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0116 · Cited by 123
CD27 Agonism Plus PD-1 Blockade Recapitulates CD4+ T-cell Help in Therapeutic Anticancer Vaccination
Ahrends, T., Bąbała, N., Xiao, Y., Yagita∥, H., van Eenennaam, H., & Borst, J. G. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3130 · Cited by 129
eIF5B drives integrated stress response-dependent translation of PD-L1 in lung cancer
Suresh, S., Chen, B., Zhu, J., Golden, R. J., Lu, C., Evers, B. M., Novaresi, N., Smith, B., Zhan, X., Schmid, V., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-0056-0 · Cited by 130
Farwell, M. D., Gamache, R. F., Babazada, H., Hellmann, M. D., Harding, J. J., Korn, R. L., Mascioni, A., Le, W., Wilson, I., Gordon, M. S., et al. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.262485 · Cited by 126
“T cells play a central role in the immune response to cancer, and tumor in fi ltration by CD8 1 T cells, either on pretreatment biopsies or during the course of therapy, has been associated with response to immunotherapy ( 4 – 8 ).”
BackgroundTargeted cancer immunotherapy with genetically engineered oncolytic Salmonella typhimurium
Guo, Y., Chen, Y., Liu, X., Min, J.-J., Tan, W., & Zheng, J. H. (2020) · Cancer Letters · doi:10.1016/j.canlet.2019.10.033 · Cited by 124
Metadata
- Authors
- Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., West, A. N., Carmona, M., Kivork, C., Seja, E., Cherry, G., Gutierrez, A. J., Grogan, T. R., Mateus, C., Tomasic, G., Glaspy, J. A., Emerson, R. O., Robins, H., Pierce, R. H., Elashoff, D. A., Robert, C., & Ribas, A.
- Affiliations
- University of California, Los Angeles (US)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Inserm (FR)
- Adaptive Biotechnologies (United States) (US)
- Fred Hutch Cancer Center (US)
- Corresponding author
- Tumeh, Paul C.
- Ribas, Antoni
- ORCID
- Venue
- Nature
- Published
- 2014-11-26
- Volume
- 515
- Issue
- 7528
- Pages
- 568-571
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4246418
- OpenAlex
- W2039123767
- Semantic Scholar
- 2c96ca62d538ff43fce01bc848fc018f6ae2b4a0
- Cited by
- 6,609
- References
- 24
- Citations by year
- 2026: 280 · 2025: 398 · 2024: 491 · 2023: 588 · 2022: 695 · 2021: 768 · 2020: 800 · 2019: 610 · 2018: 593 · 2017: 566 · 2016: 488 · 2015: 303 · 2014: 12
- FWCI
- 220.45
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- American Association for Cancer Research (SU2C-AACR-DT1012)
- Cancer Research Institute (SU2C-AACR-DT1012, CA16042)
- Melanoma Research Alliance (SU2C-AACR-DT1012)
- Adaptive Biotechnologies
- Institut Gustave-Roussy
- Sociedad Española de Oncología Médica
- National Institutes of Health (UL1TR000124, 5u54ca119347-03, P30 CA- 16042, SU2C-AACR-DT1012, CA16042)
- Stand Up To Cancer (SU2C-AACR-DT1012))
- National Cancer Institute (U54-CA119347, P01CA168585, P30-CA16042, R01CA170689, P30CA016042)
- National Institute of Allergy and Infectious Diseases (K08AI091663)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- pembrolizumab, adaptive immune resistance, CD8+ T cells, PD-L1, PD-1/PD-L1 axis, metastatic melanoma, tumor-infiltrating lymphocytes, T cell receptor repertoire, predictive biomarkers, tumor regression, immune checkpoint inhibitors
- MeSH terms
- Aged, Aged, 80 and over, Female, Humans, Immunotherapy, Male, Melanoma, Middle Aged, Models, Biological, Biomarkers, Gene Expression Regulation, Neoplastic, Multivariate Analysis, Treatment Outcome, CD8-Positive T-Lymphocytes, Cell Proliferation, Adaptive Immunity, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
